Mechanism of Action & Potential Impact of Tislelizumab | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Mechanism of Action & Potential Impact of Tislelizumab | Targeted …
6 months ago
targetedonc.com
Foundations of cGVHD Diagnosis and Severity Assessment | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Foundations of cGVHD Diagnosis and Severity Assessment | Target…
3 months ago
targetedonc.com
Managing Toxicity and the Importance of Multidisciplinary Care | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Managing Toxicity and the Importance of Multidisciplinary Ca…
1 month ago
targetedonc.com
Dr Michael Wang Traces MCL Therapy Evolution Before CAR T | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Dr Michael Wang Traces MCL Therapy Evolution Before CAR T | …
4 weeks ago
targetedonc.com
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in M…
5 months ago
targetedonc.com
MajesTEC-3 Trial Results - Efficacy and Safety Profile of Teclistamab-Daratumumab | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
MajesTEC-3 Trial Results - Efficacy and Safety Profile of Teclistamab-…
1 month ago
targetedonc.com
Case Presentation: A 72-Year-Old Woman With Metastatic Colorectal Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Case Presentation: A 72-Year-Old Woman With Metastatic Colorecta…
Oct 4, 2021
targetedonc.com
Case Presentation: A 57-Year-Old Woman With Ovarian Cancer | Tar…
Sep 23, 2021
targetedonc.com
Drawing Comparisons for Relevant Therapies in Patients With DLBCL …
Dec 9, 2024
targetedonc.com
Understanding JZP898: A Breakthrough mRNA Therapy for …
Aug 16, 2024
targetedonc.com
Risk of Recurrence in Stage 3B CRC | Targeted Oncology - Immunother…
Oct 7, 2016
targetedonc.com
Choosing Between Atezolizumab and Pembrolizumab in Lung Canc…
Jul 2, 2018
targetedonc.com
ELCC 2026: TOP Study, Sac-TMT, and the Future of EGFR-Mutant NS…
1 month ago
targetedonc.com
A 52-Year-Old Woman With HER2-Positive Breast Cancer | Targeted …
May 22, 2019
targetedonc.com
The Targeted Pulse: Two Breakthrough Therapy Designatio…
Jun 2, 2024
targetedonc.com
GIST: Treatment Considerations | Targeted Oncology - Immunothera…
Jun 22, 2020
targetedonc.com
Managing Disease Progression After TACE | Targeted Oncology - Immu…
Mar 10, 2025
targetedonc.com
Case 3: Essential Thrombocythemia (ET) | Targeted Oncology - Immun…
May 27, 2021
targetedonc.com
Challenges in Non-Small Cell Lung Cancer Treatment: Addressing Un…
Oct 16, 2023
targetedonc.com
NCCN Guidelines for Castleman's Disease | Targeted Oncology - Im…
Oct 31, 2016
targetedonc.com
Targeting PIK3CA Mutations in Breast Cancer | Targeted Oncolog…
Aug 12, 2023
targetedonc.com
Secondary Erythrocytosis Management: Differentiated Appro…
11 months ago
targetedonc.com
Multiple Myeloma Treatment: New Therapies vs Stem Cell Transplan…
Apr 3, 2024
targetedonc.com
Safety Challenges of Oncolytic Virus Therapy | Targeted Oncology - Im…
Jun 12, 2024
targetedonc.com
Evaluating Belzutifan for Clear Cell Renal Cell Carcinoma Treatment | …
Dec 15, 2024
targetedonc.com
Belumosudil Shows Sustained Efficacy and Safety for Chronic G…
Mar 11, 2024
targetedonc.com
Immunotherapy Advances in Small Cell Lung Cancer Treatment | Targ…
Mar 6, 2025
targetedonc.com
Nirogacestat Shows Statistically Significant Improvements in Desm…
Nov 28, 2023
targetedonc.com
Evolving Treatment Landscape in Metastatic Castration-Resistant Pr…
11 months ago
targetedonc.com
The Differences Between mCRPC and nmCRPC | Targeted Oncolog…
Jul 17, 2019
targetedonc.com
See more videos
Static thumbnail place holder